3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
3
Recruiting
2
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
56
Leukemia, Myeloid, Acute
38
Breast Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
37
Multiple Myeloma
31
Lymphoma, Non-Hodgkin
30
Burkitt Lymphoma
30
Lymphoma
28
Myelodysplastic Syndromes
25
Triple Negative Breast Neoplasms
23
Lymphoma, B-Cell
22
Hematologic Neoplasms
22
Recurrence
21
Lymphoma, Follicular
20
Melanoma
16
Leukemia, Lymphocytic, Chronic, B-Cell
15
Leukemia
14
Ovarian Neoplasms
13
Neoplasm Metastasis
13
Hodgkin Disease
13
Neoplasms
12
Leukemia, Biphenotypic, Acute
12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Neuroblastoma
11
Leukemia, Myelomonocytic, Chronic
11
Lymphoma, Mantle-Cell
10
Graft vs Host Disease
10
Carcinoma, Non-Small-Cell Lung
10
Sarcoma
9
Interventions
pembrolizumab
21
enfortumab vedotin
13
Gemcitabine
12
Nivolumab
8
Cisplatin
8
Carboplatin
8
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Docetaxel
5
toripalimab
4
sacituzumab govitecan
4
Paclitaxel
4
Ipilimumab
4
atezolizumab
3
Mitomycin
3
Fluorouracil
3
disitamab vedotin
2
cabozantinib
2
avelumab
2
Radiosurgery
2
Platinum
2
Injections
2
Immunotherapy
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Biopsy
2
zanidatamab
1
tremelimumab
1
tamibarotene
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Transitional Cell
×
Cyclophosphamide
×
Clear all
NCT07492628
2026-03-25
DUET-UC-NK
Beijing Biotech
Phase 1
Recruiting
42 enrolled
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled